{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.99","value":"-3.03"},{"groupId":"OG001","spread":"3.65","value":"-1.52"}]}],"title":"Change from baseline at lowest value"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.79","value":"-0.76"},{"groupId":"OG001","spread":"4.52","value":"0.00"}]}],"title":"Change from baseline at last value"}],"denoms":[{"counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"The change from baseline to the lowest and the last body weight recorded or during the the study.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received Afatinib film-coated tablets 40 mg once daily (q.d.) orally with possible dose escalation to 50 mg q.d. and dose reduction to 40 mg q.d. (if applicable), 30 mg q.d., or 20 mg q.d. (according to the protocol-defined dose-escalation and dose-reduction scheme), if required. No dose increase was allowed after dose reduction. Each treatment course was planned to be 21 days. For afatinib, patients received continuous daily dosing until disease progression, unacceptable adverse events (AEs) occurred, or withdrawal of consent for any reason.","id":"OG000","title":"Afatinib 40 Milligram (mg)"},{"description":"Patients received Gemcitabine (lyophilised powder) 1000 milligram per square metre (mg/m²) as an intravenous infusion over 30 minutes on day 1 and day 8, cisplatin (solution for infusion) 75 mg/m² as an intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles; Chemotherapy could be delayed or the dose could be reduced in accordance with the guidance in the current summary of product characteristics. For gemcitabine / cisplatin, patients were to receive a maximum of 6 treatment courses unless they developed disease progression, experienced unacceptable AEs, or withdrawal of consent for any reason.","id":"OG001","title":"Gemcitabine / Cisplatin Chemotherapy"}],"paramType":"MEAN","populationDescription":"The randomised set. Data only presented for a patient with a baseline and at least on post-baseline assessment of weight.","reportingStatus":"POSTED","timeFrame":"Baseline and throughout the study (every 3 weeks) until progression or death (whichever occurs first) up to 374 weeks.","title":"Change From Baseline in Body Weight","type":"SECONDARY","unitOfMeasure":"kilogram (kg)"}